quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:18:00·57d
PRRelease
AnaptysBio Inc. logo
Vanda Pharmaceuticals Inc. logo

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB· AnaptysBio Inc.VNDA· Vanda Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ANAB
    AnaptysBio Inc.
    Health Care
  • VNDA
    Vanda Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 5VNDAUpdateTruist$18.00
  • Jan 7ANABUpdateUBS$70.00
  • Nov 5VNDAUpdateB. Riley Securities$11.00
  • Oct 13ANABUpdateBarclays$78.00
  • Jun 4ANABUpdateH.C. Wainwright$38.00
  • Feb 4ANABUpdateWolfe Research$25.00

Related

  • SEC9h
    SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc.
  • SEC9h
    SEC Form DEF 14A filed by Vanda Pharmaceuticals Inc.
  • SEC1d
    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • PR1d
    Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
  • PR3d
    Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
  • INSIDER10d
    SEC Form 3 filed by new insider Polymeropoulos Christos Vasilios Mihael
  • INSIDER10d
    SEC Form 3 filed by new insider Howell Scott Laverne
  • PR14d
    Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022